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Abbreviations: NASH, nonalcoholic steatohepatitis, NAFLD, nonalcoholic fatty liver 
diseases, FL: fatty liver, BMI, body mass index, AST, aspartate aminotransferase, ALT, 
alanine aminotransferase, LDH, lactate dehydrogenase, γGTP, γ-glutamyl 
transpeptidase, FPG, fasting plasma glucose, HbA1c, hemoglobinA1c, ALP, alkarine 
phosphatase, type III PIIIP, procollagen N-peptide, TyIV, type IV collagen, HA, 
hyaluronic acid, TNFα, tumor necrosis factor α, ELISA, enzyme-linked immunosorbent 
assay, ROC, receiver operating characteristic, SD, standard deviation 
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ABSTRACT 
AIM: In the present study, we examined the usefulness of serum hepatic fibrosis 
markers for the diagnosis of NASH. METHODS: The subjects were 16 patients with 
NASH and 9 patients with fatty liver (FL). All were negative for serum HBsAg, 
HCVAb, antibodies related with autoimmune diseases, alcohol intake, and drug abuse. 
We measured the biochemical markers for liver function, hepatic fibrosis markers such 
as type III procollagen N-peptide (PIIIP), type IV collagen (TyIV), hyaluronic acid (HA) 
and leptin, and compared these data with histological findings of biopsy specimens. In 
addition, we examined the diagnostic efficiency of fibrosis markers and leptin for 
NASH using receiver operating characteristic (ROC) curve. Body mass index (BMI), 
fasting blood sugar, triglyceride, and degree of fat droplets, inflammation, iron 
deposition and fibrosis were significantly higher in the NASH group compared with 
the FL group. RESULTS: The diagnostic efficiencies of NASH% (cut off value) were 
68% (100ng/mL) for TyIV, 68% (10ng/mL) for HA, 64% (0.62U/mL) for PIIIP and 56% 
(8pg/mL) for leptin. CONCLUSIONS: From these results, it is suggested that the 
serum hepatic fibrosis markers such as TyIV, in addition to liver biopsy, may be useful 
for the diagnosis of NASH. 
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INTRODUCTION 
In 1979, Adler et al. reported that there are patients with liver histology similar to 
that of patients with alcoholic hepatitis or fibrosis1). In 1980, Ludwig et al.2) described 
the term of nonalcoholic steatohepatitis (NASH) from the biopsy findings in patients 
with with steatohepatitis in the absence of significant alcohol consumption.  
Estimates based on imaging and autopsy studies suggest that proximately 20~30% 
of adults in the United States and Western countries have excess fat accumulation in 
the liver. About 10 % of these individuals are eastimated to meet current diagnostic 
fibrosis and cirrhosis in a fraction, possibly up to one third, of those with NASH, and 
NASH may be a cause of cryptogenic cirrhosis3).  
The pathogenesis of NASH is multifactorial. Insulin resistance may be important 
causes of hepatocellular fat, whereas excess intracellular fatty acids, oxidant stress 
and mitochondrial dysfunction may be important causes of hepatocellular injury. From 
a recent study of biochemical and histological aspects in patients with NASH, one of 
the potential cofactors suspected to enhance oxidative stress is excessive hepatic iron 
accumulation4).  
TNFα is derived primarily from adipose tissue in the absence of active infections or 
inflammatory conditions and, under normal conditions, its plasma levels correlate 
with body fat mass. A major role of TNFα between adipose tissue and insulin 
resistance is suggested. The relative roles played by increased serum cytokines such as 
TNFα in mediating insulin resistance remains a major unresolved issue. 
Leptin may play an important role in regulating the partitioning of fat between 
mitochondrial β-oxidation and triglyceride synthesis. In the normal human liver, 
leptin is hardly visible. Defects in leptin signaling are associated with preferential 
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accumulation of fat and impaired β-oxidation of fat in the liver. In NASH, it is 
suggested that leptin is necessary for the development of fibrosis5, 6). On the other 
hand, Chitturi et al. reported that circulating leptin in patients with NASH correlates 
with hepatic steatosis but not hepatic fibrosis7). 
The diagnostic criteria for biopsy include establishing the diagnosis and staging of 
the injury, but strict guidelines do not exist. Liver enzymes are insensive and cannot 
be used reliably to confirm the diagnosis or stage the extent of fibrosis. The research 
agenda for the future includes identifying better noninvasive predictors of disease, and 
defining effective therapy. 
In the present study, we compared liver biopsy specimens with serum levels of 
hepatic fibrosis markers such as type III procollagen-N-peptide (PIIIP), type IV 
collagen (TyIV) and hyaluronic acid (HA), and investigated the diagnostic efficiency of 
serum fibrosis markers for diagnosing patients with NASH. 
 
Subjects 
Subjects for this study consisted of 25 patients（11 male and 14 female）with 
nonalcoholic fatty liver diseases (NAFLD). They were negative for hepatitis B surface 
antigen, hepatitis B core antigen, hepatitis C virus antibody, anti-nuclear antibody, 
anti-mitochondria antibody and drug abuse. In all of them, fatty liver were recognized 
by ultrasound of abdomen, and diagnosis was based on a liver biopsy. 
Provide assurance that informed consent in writing was obtained from each patient 
and the study protocol conformed to the ethical guide-lines of the 1975 Declaration of 
Helsinki as reflected in a priori approval by the appropriate institutional review 
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committee. 
Liver histology 
  The liver biopsies of all subjects were performed using a Silvermann needle. 
Histological sections were stained with hematoxylin-eosin, and Azan-Mallory stain. 
Biopsy specimens were evaluated by two hepatopathologists (Y. M., T. U.) without 
information about the background of the patients. Next, we analyzed the specimens 
according to the criteria described by Tetri et al.8), and assessed the following features 
in each case. That is, class 1 constitutes simple steatosis, class 2 is steatosis with 
lobular inflammation, class 3 requires the additional presence of ballooned 
hepatocytes, and class 4 requires the presence of either Mallory’s hyaline or fibrosis. 
Within this system, class 2, 3 and 4 are regarded as a NASH group, and class 1 as a 
FL group. From the above cliteria, 9 patients (5 male and 4 female) were diagnosed as 
having fatty liver (FL) and 16 patients （6 male and 10 female）had NASH. They had 
the history of consumption of less than 20 g per day of alcohol. 
Next, we assessed the following features in each case according to the criteria 
described by Brunt et al.9): 
Steatosis and inflammation 
The degree of steatosis, ballooning hepatocytes, lobular inflammation, portal 
inflammation, lipogranuloma, nuclear vacuoles, acidophilic bodies, Mallory bodies, and 
neutrophil infiltration in sinusoids were scored from grade 1 to 3. 
Staging for fibrosis 
Stage 1： perisinusoidal / pericellular fibrosis in Zone 3 
Stage 2： perisinusoidal / pericellular fibrosis with focal or extensive fibrosis in Zones 2 
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and 3. 
Stage 3：  perisinusoidal / pericellular fibrosis and portal fibrosis with focal or 
extensive bridging fibrosis.  
Stage 4：Cirrhosis. 
 
Physical and laboratory examinations 
  Blood samples were collected on the day of the liver biopsy, and stored at -80℃ until 
measurement. Body mass index (BMI), plasma glucose, aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), γ glutamyl 
transpeptidase (γGTP), fasting plasma glucose (FPG), hemoglobinA1 (HbA1c), insulin, 
lactate dehydrogenase (LDH), alkarine phosphatase  (ALP), iron, ferritin 
triglycedride and total cholesterol were examined. All laboratory analyses were 
performed by standard clinical laboratories. 
  In addition, type III procollagen N-peptide (PIIIP), type IV collagen (TyIV), 
hyaluronic acid (HA), leptin in sera were measured. That is, serum PIIIP levels were 
measured with a radioimmunoassay kit (Bering-Hochest, Frankfurt, Germany). 
Serum T4 levels were measured with a one stepsandwich enzyme immunoassay 
(Daiichi Chemical Phayma. Ltd. Tokyo, Japan). Serum HA levels were determined by 
a sandwich enzyme binding assay (Chugai Diagnostics Science Co. Ltd, Tokyo, Japan). 
Serum leptin levels were measured with a radioimmunoassay kit (LINCO Research 
Inc., ST Charles, Missouri, USA). Serum tumor necrosis factor α (TNFα) levels were 
measured with a enzyme-linked immunosorbent assay (ELISA) kit (Nihon Kotai Inc. 
Tokyo, Japan). 
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Study design 
We compared the liver histology in the NASH group with that in the FL group. Next, 
to assess the ability of these serum markers for differentiating NASH from FL, we 
calculated the sensitivity and the specificity for each value of each test and then 
constructed the receiver operating characteristic (ROC) curves by plotting the 
sensitivity against the reverse specificity (100-specificity) at each value. The nearer a 
curve shifts to the top left-hand corner of the graph, the more useful test diagnosis of 
NASH is that which maximizes the sum of the sensitivity and specificity. 
 
Statistical analysis 
Data were expressed as mean ± SD. Statistical analysis was performed with the 
non-parametric Mann-Whitney U-test using the Statistics software package. 
Statistical significance was set at p<0.05. Spearman’s correlation analysis was used to 
examine the correlations between data sets. 
 
RESULTS 
1. Clinical characteristics and blood chemistry in NASH and FL groups 
In the clinical characteristics between the NASH and FL groups, BMI in the NASH 
group was significantly higher than that in the FL group (28±3 vs 25±4, p<0.05). On 
the other hand, there were no significances in age and gender between the two groups. 
In the blood chemistry between the NASH and FL groups, serum triglyceride and 
total cholesterol levels in the NASH group were significantly high compared with 
those in the FL group (triglyceride; 186±91 vs 107±29, p<0.05,; FPG; 118±25 vs 92±16, 
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p<0.05). However, there were no significances in serum AST, ALT and total cholesterol 
levels between the two groups (Table 1). 
 
2. Serum hepatic fibrosis markers, leptin, iron, ferittin and TNFα in NASH and FL 
groups 
  There were no significances in serum hepatic fibrosis markers, leptin, iron, 
ferittin and TNFα between NASH and FL groups (Table 2). 
 
3. Correlation between liver histological findings and serum hepatic fibrosis markers 
in patients with NAFLD  
We performed statistical analysis for the correlation between liver histological 
findings and serum hepatic fibrosis markers in patients with NAFLD. Serum PIIIP 
level was significantly correlated with the degree of steatosis (p<0.05). In addition, 
serum TyIV levels were significantly correlated with the degrees of steatosis, 
pericellular fibrosis and perivenular fibrosis (respectively, p<0.05) (Table 3). 
 
4. Receiver-operating characteristic (ROC) curves of serum PIIIP, TyIV, HA and 
leptin levels predicting NASH and its efficiency in patients with NAFLD  
  When the ability of these serum markers to detect NASH in patients with NAFLD 
was assessed with a ROC curve, the best was the serum TyIV test, and second was the 
serum HA test (Figure 1).  
  At a cut-off value of 100ng/mL, serum TyIV level was 68.8% in sensitivity and 66.7% 
in specificity. Also, serum HA level was 75.0% in sensitivity and 55.6% in specificity at 
a cut-off value of 10ng/mL. For serum PIIIP level, at a cut-off value was 0.62 U/mL, 
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PIIIP level was 52.6% in sensitivity and 33.3% in specificity, and for serum leptin level, 
at a cut-off value 8 ng/mL, sensitivity was 62.5% and specificity 44.4% (Figure 1 and 
Table 4).  
  In addition, the diagnostic efficiencies predicting NASH at these cut-off values were 
68% for TyIV, 68% for HA, 64% for PIIIP and 56% for leptin (Table 4). However, the 
cut-off values of HA, PIIIP and leptin showed normal ranges. 
 
DISCUSSIONS 
  The term NASH, coined by Ludwig et al.2) in 1980 to describe the biopsy findings in 
patients with steatohepatitis in the absence of significant alcohol consumption, has 
served the field well10). Recently three criteria have proposed for the diagnosis of 
NASH: 1) a histological picture of steatohepatitis, 2) convincing evidence of minimal or 
no alcohol consumption (<40g/wk), and 3) absence of serological evidence of viral 
hepatitis. Each of the criteria has limitations.  
That is, the histological criteria for the diagnosis of steatohepatitis include 
macrovesicular steatosis; evidence of ballooning degeneration; Mallory bodies; scatterd 
predominantly lobular, inflammatory infiltrate; and perisinusoidal fibrosis. 
Determinaning the extent of alcohol consumption is no easy task. Direct and surrogate 
markers of alcohol consumption include serum γ-glutamyltransferase level, AST and 
ALT levels, AST/ALT ratio, mitochondrial AST and so on. The presence of non-A, 
non-B and non-C was originally believed to constitute an exclusion criterion for the 
diagnosis of NASH11). 
However, no accurate noninvasive methods can diagnose NASH because the 
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presence, degree, and pattern of transaminase level elevation are non-specific and do 
not provide a specific diagnosis. Incidentally, necroinflammation and intralobular 
fibrosis containing the perisinusoidal fibrosis are histological characteristics of NASH. 
Serum hepatic fibrosis markers such as PIIIP, TyIV and HA are increased in patients 
with chronic liver diseases, indicating that these serum markers are of value for 
dedtecting altered connective tissue metabolism in liver fibrosis. Especially, increased 
levels of serum PIIIP and TyIV appear to be associated with active hepatic 
fibrogenesis12), and increased levels of serum HA reflects the cirrhotic liver and 
sinusoidal capillarization13). In the present study, we investigated the usefulness of 
hepatic fibrosis markers for the noninvasive diagnosis of NASH. In results, The 
diagnostic efficiencies of NASH% (cut off level) were 70% (100ng/mL) for TyIV, 68% 
(10ng/mL) for HA, 64% (0.62U/mL) for PIIIP and 56% (8pg/mL) for leptin. It is suggested 
that the hepatic fibrosis markers such as TyIV, in addition to liver biopsy, may be useful 
for the diagnosis of NASH. 
Many issues remain unresolved regarding the diagnosis of NASH. The need for a 
liver biopsy to diagnose NASH in routine clinical practice is debatable. Arguments 
against a liver biopsy include the generally good prognosis of most patients with 
NASH, and risks and costs associated with biopsy. Although our results need to be 
repeated by another centre, we think that the number of biopsies in the diagnosis and 
management of NASH could be reduced if serum hepatic fibrosis markers are 
measured. 
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FIGURE LEGENDS 
Fig. 1 Receiver operating characteristic (ROC) curves showing serum PIIIP, TyIV, HA, 
and leptin levels in predicting NASH in patients with NAFLD 
When the ability of these serum markers to detect NASH in patients with NAFLD is 
assessed with a receiver operating characteristic (ROC) curve.  
  At a cut-off value of 100ng/mL, serum TyIV level was 68.8% in sensitivity and 66.7% 
in specificity. Also, serum HA level was 75.0% in sensitivity and 55.6% in specificity at 
a cut-off value of 10ng/mL. For serum PIIIP level, at a cut-off value was 0.62 U/mL, 
PIIIP level was 52.6% in sensitivity and 33.3% in specificity, and for serum leptin level, 
at a cut-off value 8 ng/mL, sensitivity was 62.5% and specificity 44.4%. 
